Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial of tideglusib in Alzheimer's disease.
Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators. Lovestone S, et al. J Alzheimers Dis. 2015;45(1):75-88. doi: 10.3233/JAD-141959. J Alzheimers Dis. 2015. PMID: 25537011 Clinical Trial.
Prediction of Alzheimer's disease biomarker status defined by the 'ATN framework' among cognitively healthy individuals: results from the EPAD longitudinal cohort study.
Calvin CM, de Boer C, Raymont V, Gallacher J, Koychev I; European Prevention of Alzheimer’s Dementia (EPAD) Consortium. Calvin CM, et al. Among authors: raymont v. Alzheimers Res Ther. 2020 Nov 9;12(1):143. doi: 10.1186/s13195-020-00711-5. Alzheimers Res Ther. 2020. PMID: 33168064 Free PMC article.
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease.
Koychev I, Lawson J, Chessell T, Mackay C, Gunn R, Sahakian B, Rowe JB, Thomas AJ, Rochester L, Chan D, Tom B, Malhotra P, Ballard C, Chessell I, Ritchie CW, Raymont V, Leroi I, Lengyel I, Murray M, Thomas DL, Gallacher J, Lovestone S. Koychev I, et al. Among authors: raymont v. BMJ Open. 2019 Mar 23;9(3):e024498. doi: 10.1136/bmjopen-2018-024498. BMJ Open. 2019. PMID: 30904851 Free PMC article.
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E; TOMMORROW study investigators. Burns DK, et al. Lancet Neurol. 2021 Jul;20(7):537-547. doi: 10.1016/S1474-4422(21)00043-0. Lancet Neurol. 2021. PMID: 34146512 Clinical Trial.
Patient attitudes towards remote memory clinic assessment.
Blane J, ClareO'Donoghue M, Craig E, Clarke L, Raymont V, Mackay C, Martos L. Blane J, et al. Among authors: raymont v. Alzheimers Dement. 2021 Dec;17 Suppl 11:e053742. doi: 10.1002/alz.053742. Alzheimers Dement. 2021. PMID: 34971057
Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.
Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brašić JR, Zhou Y, Raymont V, Kumar A, Ravert HT, Dannals RF, Pontecorvo MJ, Skovronsky DM, Lyketsos CG. Rosenberg PB, et al. Among authors: raymont v. Am J Geriatr Psychiatry. 2013 Mar;21(3):272-8. doi: 10.1016/j.jagp.2012.11.016. Am J Geriatr Psychiatry. 2013. PMID: 23395194 Free PMC article.
85 results